ERBB2 and breast carcinoma: For instance, the combination of HCQ + Abemaciclib (CDK4/6 inhibitor) +/− endocrine therapy suggests a positive outcome for clinical trial in HR-positive/HER2- breast cancer lesions (NCT04316169) [189].